Financing ·
Zai Lab prices $250M PIPE of 11.34M ADSs at $22.04 each to fund zoci development
ZLABZai Lab Ltd
Zai Lab Limited entered into a securities purchase agreement for the private sale of 11,340,000 American Depositary Shares (ADSs) to accredited investors in a PIPE transaction priced at $22.04 per ADS. The company expects to receive approximately $250 million in gross proceeds before deducting placement agent fees and other offering expenses. The closing is expected on or about October 27, 2026, subject to customary conditions. Net proceeds will primarily support the global development of zocilurtatug pelitecan (zoci), a DLL3-targeting antibody-drug conjugate, for working capital and general corporate purposes. Zai Lab Limited is an innovation-driven biopharmaceutical company focused on discovering and commercializing products in oncology, immunology, neuroscience, and infectious disease.